pharmaphorum

APRIL 1, 2022

With the new Health and Care Bill edging ever closer to receiving Royal Assent, life sciences companies in the UK are preparing to navigate the most significant piece of NHS legislation in a decade. The new bill, which is expected to come into force on 1st July, will see Clinical Commissioning Groups replaced with Integrated Care Systems (ICSs) as statutory bodies across England.

98

98

Pharma Times

APRIL 1, 2022

Study demonstrates ability of the Parsortix system to isolate circulating tumour cells, targeting the metastatic spread of cancer

44

44

pharmaphorum

APRIL 1, 2022

NICE has reversed its stance on UCB and Amgen’s severe osteoporosis therapy Evenity, saying out can be prescribed on the NHS for women with the disease in England and Wales who are at high risk of fractures. The move – which comes after an agreement by UCB to reduce the price of the drug – makes Evenity (romosozumab) the first novel therapy for the bone-wasting condition to be available to the NHS across the UK in more than a decade.

Documentation 59

Documentation 59

Pharma Times

APRIL 1, 2022

New technology could reduce finger pricking by 50% while also providing patients with continuous data about blood sugar levels

43

43

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

APRIL 1, 2022

The search for an alternative to opioid drugs for pain relief has dragged one for decades, with little success, but Vertex Pharma thinks that could be about to change. The company has become the first to demonstrate that a drug targeting the NaV1.8 sodium channel is more effective than placebo at reducing pain in proof-of-concept studies, paving the way for larger studies that could be used to support regulatory filings.

59

59

Policy Prescription

APRIL 1, 2022

The U.S. Department of Justice, according to Seeking Alpha , is investigating the sale and distribution of counterfeit drugs in the U.S. that may have amounted to a quarter-billion dollars. The investigation comes about two months after The Wall Street Journal reported on a lawsuit filed by Gilead Sciences alleging a massive breach in the U.S. drug supply chain consisting of $250 million in counterfeit HIV drugs that were sold throughout the U.S. from licensed pharmacies to American patien

FDA 40

FDA Documentation 40